SAM #75A50126C00001

Award for Advanced Development and Procurement of MARV Monovalent Vaccine for BARDA

This award supports the advanced development and procurement of a MARV (Marburg virus) monovalent vaccine for the Department of Health and Human Services (HHS), specifically through BARDA. - Government Buyer: - Department of Health and Human Services (HHS) - Office of Assistant Secretary for Preparedness and Response - Biomedical Advanced Research and Development Authority (BARDA) - OEM/Vendor: - Albert B. Sabin Vaccine Institute, Inc. - Products/Services Requested: - Advanced development of MARV monovalent vaccine - FDA licensure of the vaccine - Procurement, shipping, and vendor managed inventory (VMI) storage - No specific part numbers or quantities provided - Notable Requirements: - Hybrid cost reimbursement/fixed price contract structure due to undefined requirements - Emphasis on advanced development and regulatory approval (FDA licensure) - Vendor managed inventory (VMI) storage included - Place of Performance: - Washington, DC - Contract Value: - Total award amount: $1,042,099,118

Description

This acquisition will allow BARDA to invest Project BioShield funds for the advanced development, US Food and Drug Administration (FDA) licensure, procurement, shipping, and vendor managed inventory (VMI) storage of MARV monovalent vaccine.

This contract was awarded on a hybrid cost reiumbursement/fixed price basis as circumstances do not allow the agency to define its requirements sufficiently to allow for a fixed-price type contract.

View original listing